{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:27:04Z","timestamp":1790836024652,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jaad.2016.10.044","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T11:49:16Z","timestamp":1484308156000},"page":"863-870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":147,"title":["Vitiligo-like lesions occurring in patients receiving anti-programmed cell death\u20131 therapies are clinically and biologically distinct from vitiligo"],"prefix":"10.1016","volume":"76","author":[{"given":"Maiana","family":"Larsabal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Jacquemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Rambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Thiolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Dousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorilla","family":"Prey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Boniface","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.10.044_bib1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2016.10.044_bib2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2016.10.044_bib3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2016.10.044_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2016.10.044_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.10.044_bib6","first-page":"160","article-title":"Clinical practice. Vitiligo","volume":"360","author":"Taieb","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2016.10.044_bib7","doi-asserted-by":"crossref","first-page":"279ra39","DOI":"10.1126\/scitranslmed.3010302","article-title":"Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells","volume":"7","author":"Watanabe","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaad.2016.10.044_bib8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/pcmr.12219","article-title":"Type I interferon signature in the initiation of the immune response in vitiligo","volume":"27","author":"Bertolotti","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaad.2016.10.044_bib9","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaad.2016.10.044_bib10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2016.10.044_bib11","first-page":"44","article-title":"New insights into immune mechanisms of vitiligo","volume":"151","author":"Boniface","year":"2016","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.10.044_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0749.2006.00355.x","article-title":"VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force","volume":"20","author":"Taieb","year":"2007","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.jaad.2016.10.044_bib13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/pcmr.12065","article-title":"Development and validation of the K-VSCOR for scoring Koebner's phenomenon in vitiligo\/non-segmental vitiligo","volume":"26","author":"Diallo","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaad.2016.10.044_bib14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/bjd.12166","article-title":"Autoimmune thyroid disease\u00a0in vitiligo: multivariate analysis indicates intricate pathomechanisms","volume":"168","author":"Gey","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.10.044_bib15","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/pcmr.12161","article-title":"Melanoma-associated leukoderma - immunology in black and white?","volume":"26","author":"Naveh","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaad.2016.10.044_bib16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00002371-199601000-00009","article-title":"Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy","volume":"19","author":"Rosenberg","year":"1996","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"10.1016\/j.jaad.2016.10.044_bib17","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","article-title":"PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines","volume":"72","author":"Peng","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2016.10.044_bib18","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI44849","article-title":"Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma","volume":"121","author":"Byrne","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2016.10.044_bib19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1034\/j.1600-0749.2003.00070.x","article-title":"A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?","volume":"16","author":"Gauthier","year":"2003","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.jaad.2016.10.044_bib20","doi-asserted-by":"crossref","first-page":"15011","DOI":"10.1038\/nrdp.2015.11","article-title":"Vitiligo","volume":"1","author":"Picardo","year":"2015","journal-title":"Nat Rev Dis Primers"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216310209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216310209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:43:55Z","timestamp":1759272235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216310209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0190962216310209"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.10.044","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death\u20131 therapies are clinically and biologically distinct from vitiligo","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.10.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}